Clinical Trial Update: Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating isatuximab in patients with monoclonal gammopathy of renal significance is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy
• Monoclonal Gammopathy of Renal Significance

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: Columbia University | Conditions: Monoclonal Gammopathy | Phase 2 | Status: RECRUITING